Evozyne

Evozyne is a private, pre-clinical stage biotech leveraging a closed-loop AI and high-throughput experimentation platform to engineer novel therapeutic proteins from scratch. The company focuses on high-unmet-need immune-mediated diseases, with an initial pipeline including IgG proteases, next-generation cytokines, and respiratory disease candidates. Founded by Paragon Biosciences and led by a team with deep biopharma and AI expertise, Evozyne aims to establish AI-designed proteins as a foundational therapeutic modality.

An AI-native, closed-loop platform combining EvoGen (generative AI for de novo protein design) and EvoLab (high-throughput experimental synthesis and testing) to create and optimize novel therapeutic proteins.

Evozyne competes in the rapidly evolving field of AI-driven drug discovery, facing competition from other AI-native protein design companies like Generate Biomedicines and Absci, as well as internal efforts at large pharmaceutical companies. Its differentiation hinges on the specific capabilities of its closed-loop AI/experimental platform and its focused application to immune-mediated diseases.